LIDEX
Clinical safety rating: caution
Comprehensive clinical and safety monograph for LIDEX (LIDEX).
Glucocorticoid receptor agonist; inhibits phospholipase A2, reducing prostaglandin and leukotriene synthesis; suppresses inflammatory cytokines and immune cell migration.
| Metabolism | Hepatic via CYP3A4; primarily excreted renally as metabolites. |
| Excretion | Renal (primarily as metabolites) ~ 95%; biliary/fecal ~5%. |
| Half-life | Terminal elimination half-life: 28-36 hours. Clinical context: Steady-state achieved in ~5-7 days; once-daily dosing maintains therapeutic levels without accumulation in patients with normal renal function. |
| Protein binding | ~99% bound to plasma proteins, primarily albumin and corticosteroid-binding globulin (CBG). |
| Volume of Distribution | Vd: 1-2 L/kg, suggesting extensive tissue distribution with partition into adipose tissue. |
| Bioavailability | Topical: Limited systemic bioavailability (<1% on intact skin though higher on damaged skin). Intralesional: 100% bioavailability into systemic circulation. |
| Onset of Action | Topical: Onset of anti-inflammatory effect within 1-2 hours. Intralesional: Faster onset, within minutes to 1 hour. |
| Duration of Action | Topical: Duration of effect after single application is 8-12 hours due to depot formation in stratum corneum. Intralesional: Duration up to 3-4 weeks due to slow release from injection site. |
Apply a thin film to affected skin areas twice daily. Not for ophthalmic, oral, or intravaginal use.
| Dosage form | SOLUTION |
| Renal impairment | No dosage adjustment required for renal impairment. |
| Liver impairment | No dosage adjustment required for hepatic impairment. |
| Pediatric use | Use smallest amount effective; limit treatment duration to 2 weeks. Not recommended for children under 12 years due to higher risk of HPA axis suppression. |
| Geriatric use | Use with caution; apply smallest effective amount for shortest duration due to increased risk of skin atrophy and systemic absorption. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for LIDEX (LIDEX).
| Breastfeeding | Limited data. Topical fluocinonide may be absorbed systemically but minimal amounts likely transfer to breast milk. M/P ratio not established. Use caution; avoid application to breast area to prevent infant ingestion. Consider using lower potency corticosteroids if needed. |
| Teratogenic Risk | Topical corticosteroids, including LIDEX (fluocinonide), are generally considered low risk for teratogenicity when used as directed. However, systemic absorption can occur, especially with prolonged use, large areas, or occlusive dressings. First trimester: No well-controlled studies; animal studies show some risk with high systemic doses. Use only if potential benefit justifies risk. Second and third trimesters: Avoid prolonged or large area use; may cause fetal growth restriction or adrenal suppression if significant systemic absorption occurs. |
■ FDA Black Box Warning
None
| Serious Effects |
["Known hypersensitivity to fluocinonide or any component","Untreated bacterial, fungal, viral, or parasitic infections at application site","Rosacea, perioral dermatitis, acne vulgaris"]
| Precautions | ["Systemic absorption may cause reversible HPA axis suppression","Local irritation, atrophy, striae, and secondary infection","Use with caution in children and on face, intertriginous areas","Avoid prolonged use and occlusive dressings"] |
Loading safety data…
| Fetal Monitoring | Monitor for signs of systemic corticosteroid effects including adrenal suppression, Cushing's syndrome, hyperglycemia, and hypertension. In fetus/neonate, monitor for growth parameters if extensive maternal use. No routine fetal monitoring required for short-term, small-area use. |
| Fertility Effects | No known adverse effects on fertility with topical use. Systemic corticosteroids may impair spermatogenesis or ovulation, but topical fluocinonide at recommended doses is unlikely to affect fertility. |